Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.55 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | TACR3 | P29371 | 8/20 | 0.51 |
| ▸ | TACR1 | P25103 | 2/20 | 0.49 |
| ▸ | TACR2 | P21452 | 1/20 | 0.49 |
| ▸ | SCN1A | P35498 | 1/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.49 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | DRD5 | P21918 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4815806 | 0.84 | CYP2C19 (0.44) | OPRM1OPRL1POLBTACR3SCN1A | |
| SCHEMBL3895076 | 0.83 | TACR3 (0.57) | OPRM1OPRL1POLBFAAHTACR3 | |
| SCHEMBL3911069 | 0.82 | TACR3 (0.55) | POLBTACR3TACR1TACR2DRD2 | |
| SCHEMBL6499952 | 0.81 | DRD2 (0.67) | POLBTACR3TACR1TACR2DRD2 | |
| SCHEMBL4806364 | 0.81 | OPRM1 (0.43) | OPRM1OPRL1TACR3SCN1ASCN2A | |
| SCHEMBL4631243 | 0.81 | POLB (0.64) | OPRM1OPRL1POLBTACR3TACR1 | |
| SCHEMBL2921064 | 0.80 | OPRM1 (0.80) | OPRM1OPRL1POLBSCN1ASCN2A | |
| Hydrochloric Acid SCHEMBL9317938 | 0.80 | POLB (0.62) | OPRL1POLBTACR3TACR1TACR2 | |
| SCHEMBL3897576 | 0.80 | CYP2C19 (0.67) | POLBFAAHTACR3 | |
| SCHEMBL904881 | 0.80 | OPRM1 (0.73) | OPRM1OPRL1FAAHTACR3TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468368-B2 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI AVENTIS (FR) | 2008-12-23 | — | — | US | disclosed |
| US-7294628-B2 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-11-13 | — | — | US | disclosed |
| EP-1513835-B1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2006-08-16 | — | — | EP | disclosed |
| US-20060167007-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2006-07-27 | — | — | US | disclosed |
| EP-1513836-B1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2006-05-03 | — | — | EP | disclosed |
| US-20050176722-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | US | disclosed |
| EP-1513836-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2005-03-16 | — | — | EP | disclosed |
| EP-1513835-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003104225-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003104226-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167007-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | NR5A2, NR3C2, NR3C1 | OPRM1 104/4885OPRL1 29/4885POLB 3483/4885 |
| US-20050176722-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | NR5A2, NR3C1, CBR1 | OPRM1 52/4885OPRL1 24/4885POLB 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.